599 related articles for article (PubMed ID: 2153194)
1. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
3. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
5. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
[TBL] [Abstract][Full Text] [Related]
6. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
[TBL] [Abstract][Full Text] [Related]
7. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.
Daniels JR; Chak LY; Sikic BI; Lockbaum P; Kohler M; Carter SK; Reynolds R; Bohnen R; Gandara D; Yu J
J Clin Oncol; 1984 Nov; 2(11):1192-9. PubMed ID: 6092554
[TBL] [Abstract][Full Text] [Related]
10. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
[TBL] [Abstract][Full Text] [Related]
11. Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy.
Goodman GE; Miller TP; Manning MM; Davis SL; McMahon LJ
J Clin Oncol; 1983 Aug; 1(8):483-8. PubMed ID: 6321685
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
13. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
14. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
Urtasun RC; Palmer M; Kinney B; Belch A; Hewitt J; Hanson J
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):337-42. PubMed ID: 9457818
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
Johnson DH; Bass D; Einhorn LH; Crawford J; Perez CA; Bartolucci A; Omura GA; Greco FA
J Clin Oncol; 1993 Jul; 11(7):1223-9. PubMed ID: 8391064
[TBL] [Abstract][Full Text] [Related]
16. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Bleher EA; Ludwig C; Siegenthaler P; Martinelli G; Sauter C; Schatzmann E; Senn HJ
Ann Oncol; 1994 Dec; 5(10):921-8. PubMed ID: 7696164
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
[TBL] [Abstract][Full Text] [Related]
18. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with cyclophosphamide, vincristine, cisplatin and etoposide (COPE) combined with radiotherapy for small cell lung cancer.
Nam YJ; Choi CW; Shin SW; In KH; Kang KH; Kim JS; Choi YH; Kim CY; Choi MS
Korean J Intern Med; 1995 Jan; 10(1):32-7. PubMed ID: 7626554
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]